Abcam, ab265135, Human SUGP2 (SFRS14) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
SUGP2 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 459 bp deletion in exon 3. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 459 bp deletion in exon 3,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SUGP2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SFRS14 also known as SUGP2 is a protein involved in RNA splicing processes. It facilitates the assembly of spliceosomal complexes which are important in removing introns from pre-mRNA transcripts. The molecular mass of SFRS14 is approximately 111 kDa. This protein expresses widely in human tissues with significant expression in the brain heart and reproductive tissues. Its function in these tissues indicates it plays an important role in post-transcriptional gene regulation.
Biological function summary
SFRS14 influences the regulation of alternative splicing by interacting with other splicing factors. It acts as part of the spliceosome complex which is responsible for the precise cutting and joining of exons from mRNA precursors. SFRS14 ensures the correct splicing of transcripts related to various cellular functions. Its role in alternative splicing helps generate protein diversity which is essential in maintaining cellular processes and adaptation to different physiological conditions.
Pathways
This protein takes part in the mRNA processing pathway and the gene expression pathway. In the mRNA processing pathway SFRS14 assists in accurately assembling the spliceosome ensuring proper splicing of precursor mRNA. Relating to other proteins in these pathways SFRS14 interacts with members of the SR protein family which includes proteins like SFRS1 and SFRS2. These interactions highlight its contribution to the regulation of gene expression through mRNA maturation.
Several cases relate improper function of SFRS14 to specific pathologies like cancer and neurological conditions. In cancer aberrant alternative splicing events which involve SFRS14 alter the expression of genes that control cell growth and apoptosis. The SFRS14 protein connects to the BCL2 family of proteins which play a role in apoptotic processes in cancer cells. Similarly disruptions in SFRS14 function have been observed in neurodegenerative diseases where it may affect neuronal survival and plasticity due to faulty splicing of essential neuronal transcripts.